+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Indication for sentinel lymph node biopsy for breast cancer when core biopsy shows ductal carcinoma in situ



Indication for sentinel lymph node biopsy for breast cancer when core biopsy shows ductal carcinoma in situ



American Journal of Surgery 202(1): 59-65



The use of sentinel lymph node biopsy (SLNB) for ductal carcinoma in situ (DCIS) is controversial. A total of 103 primary breast cancer patients who were diagnosed with DCIS by needle biopsy preoperatively and underwent initial SLNB were analyzed retrospectively. No sentinel nodal metastasis was detected in 66 patients with the final diagnosis of DCIS. However, 2 (5.4%) of 37 patients with invasive ductal carcinoma at final diagnosis had positive sentinel nodes. Multivariate logistic regression analysis identified 2 independent significant predictors of existence of invasive components: presence of a palpable tumor (odds ratio, 4.091; 95% confidential interval, 1.399-11.959; P = .010) and tumor size of 2.0 cm or larger on magnetic resonance imaging (odds ratio, 4.506; 95% confidence interval, 1.322-15.358; P = .016). Initial SLNB should be considered for patients diagnosed with DCIS by needle biopsy when they have a high risk for harboring invasive ductal cancer preoperatively.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036143411

Download citation: RISBibTeXText

PMID: 21741518

DOI: 10.1016/j.amjsurg.2010.09.032


Related references

Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. Current Surgery 62(2): 253-257, 2005

Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy. Annals of Surgical Oncology 21(1): 66-73, 2014

Predictors of invasive breast cancer in mammographically detected microcalcification in patients with a core biopsy diagnosis of flat epithelial atypia, atypical ductal hyperplasia or ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy. Pathology, Research and Practice 208(4): 217-220, 2012

Sentinel lymph node biopsy is not warranted following a core needle biopsy diagnosis of ductal carcinoma in situ (DCIS) of the breast. Breast 24(3): 197-200, 2016

Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer 107(8): 1760-1768, 2006

The impact of sentinel lymph node biopsy in patients with a core biopsy diagnosis of ductal carcinoma in situ. Breast Cancer 17(4): 276-280, 2011

Sentinel lymph node biopsy in patients with a needle core biopsy diagnosis of ductal carcinoma in situ: is it justified?. Journal of Clinical Pathology 62(6): 534-538, 2009

The utility of sentinel lymph node biopsy in patients with ductal carcinoma in situ suspicious for microinvasion on core biopsy. Annals of Surgical Oncology 22(1): 59-65, 2015

Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. Journal of the American College of Surgeons 200(4): 516-526, 2005

Sentinel lymph node biopsy is not necessary in patients diagnosed with ductal carcinoma in situ of the breast by stereotactic vacuum-assisted biopsy. Breast Cancer 23(2): 190-194, 2016

Prediction of underestimated invasiveness in patients with ductal carcinoma in situ of the breast on percutaneous biopsy as rationale for recommending concurrent sentinel lymph node biopsy. Breast 22(4): 537-542, 2014

Prediction of underestimated invasiveness in patients with ductal carcinoma in situ of the breast on percutaneous biopsy as rationale for recommending concurrent sentinel lymph node biopsy. The Breast 22(4): 537-542, 2013

Is there an indication for sentinel node biopsy in patients with ductal carcinoma in situ of the breast? A review. European Journal of Cancer 43(6): 993-1001, 2007

Sentinel lymph node biopsy in ductal carcinoma in situ of the male breast. Breast Journal 11(2): 154, 2005

The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ or with locally advanced breast cancer receiving neoadjuvant chemotherapy. Cancer Control 11(4): 231-235, 2004